Philip Dormitzer, new GSK global head of vaccines R&D

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

Glax­o­SmithK­line has ap­point­ed Philip Dor­mitzer, for­mer­ly chief sci­en­tif­ic of­fi­cer of Pfiz­er’s vi­ral vac­cines unit, as its newest glob­al head of vac­cines R&D, look­ing to lever­age one of the lead­ing minds be­hind Pfiz­er and BioN­Tech’s RNA col­lab­o­ra­tion that led to Covid-19 jab Comir­naty, the British drug gi­ant said Tues­day.

Dor­mitzer had been with Pfiz­er for a lit­tle more than six years, join­ing up af­ter a sev­en-year stint with No­var­tis, where he reached the role of US head of re­search and head of glob­al vi­rol­o­gy for the com­pa­ny’s vac­cines and di­ag­nos­tics unit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.